Selvester score predicts implantable cardioverter defibrillator shocks in patients with non-ischemic cardiomyopathy

被引:1
|
作者
Arisoy, Fazil [1 ]
Ozcan Celebi, Ozlem [2 ]
Erbay, Ilke [2 ]
Tufekcioglu, Omac [2 ]
Aydogdu, Sinan [2 ]
Temizhan, Ahmet [2 ]
机构
[1] Kilis State Hosp, Dept Cardiol, Kilis, Turkey
[2] Univ Hlth Sci, Ankara City Hosp, Dept Cardiol, Ankara, Turkey
关键词
ICD; non ischemic cardiomyopathy; Selvester score; shock; SUDDEN CARDIAC DEATH; QRS SCORE; PRIMARY PREVENTION; THERAPY; MANAGEMENT; AMIODARONE;
D O I
10.1002/joa3.12571
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: The implantable cardiac defibrillator is the cornerstone of prevention of sudden cardiac death in non-ischemic cardiomyopathy. The Selvester score, which is frequently investigated in ischemic cardiomyopathy, has not been investigated in the field of non-ischemic cardiomyopathy. Aim: The aim of this study was to evaluate the Selvester score for determining appropriate implantable cardiac defibrillator shocks in non-ischemic cardiomyopathy patients. Materials and methods: In all, 131 non-ischemic cardiomyopathy patients were included in the study. A simplified Selvester score was calculated from ECG data. Patients were divided into two groups according to whether they received ICD shock. Results: Of the patients, 28.2% received appropriate implantable cardiac defibrillator shock. The Selvester score was significantly higher in patients receiving appropriate shock when compared to patients with no implantable cardiac defibrillator shocks (8.8 +/- 4.6 vs 7.2 +/- 3.3, P = .040). The median QRS duration was significantly longer in patients receiving appropriate shock than in patients with no shocks (130.14 +/- 35.08 ms vs 120.12 +/- 20.57 ms, P = .045). We determined that the cutoff value for the Selvester score to predict ICD shocks was 6.5 with a sensitivity of 72.0% and a specificity of 83% (AUC = 0.717; %95 GA: 0.627-0.807, P < .001). Conclusion: Selvester score was higher in patients receiving appropriate shock than in patients who did not receive any implantable cardiac defibrillator shock. From this study, the Selvester score is associated with the risk of ventricular tachycardia/ventricular fibrillation in non-ischemic cardiomyopathy so that careful attention is necessary to manage the patients with high Selvester score.
引用
收藏
页码:1046 / 1051
页数:6
相关论文
共 50 条
  • [1] Right Bundle Branch Block Predicts Appropriate Implantable Cardioverter Defibrillator Therapies in Patients with Non-Ischemic Dilated Cardiomyopathy and a Prophylactic Implantable Cardioverter Defibrillator
    Jimenez-Blanco Bravo, Marta
    Salinas, Gonzalo Luis Alonso
    Esteban, Carolina Parra
    Ramos, Jorge Toquero
    Luque, Miguel Amores
    Gomez, Jose Luis Zamorano
    Garcia-Izquierdo, Eusebio
    Alvarez-Garcia, Jesus
    Lozano, Ignacio Fernandez
    Urda, Victor Castro
    DIAGNOSTICS, 2024, 14 (11)
  • [2] Impact of implantable cardioverter defibrillator on survival in patients with non-ischemic dilated cardiomyopathy
    Kataoka, Naoya
    Imamura, Teruhiko
    CLINICAL CARDIOLOGY, 2023, 46 (10) : 1296 - 1296
  • [3] Implantable cardioverter defibrillator therapy in patients with ischemic or non-ischemic cardiomyopathy and nonsustained ventricular tachycardia
    Evonich, RF
    Maheshwari, A
    Gardiner, JC
    Khasnis, A
    Kantipudi, S
    Ip, JH
    Grimes, D
    Hayter, G
    Thakur, RK
    JOURNAL OF INTERVENTIONAL CARDIAC ELECTROPHYSIOLOGY, 2004, 11 (01) : 59 - 65
  • [4] Appropriate therapy in primary prevention implantable cardioverter defibrillator patients with ischemic and non-ischemic cardiomyopathy
    Mattsson, G.
    Kader, R.
    Pournaras, A.
    Magnusson, P.
    EUROPEAN HEART JOURNAL, 2018, 39 : 216 - 216
  • [5] Implantable Cardioverter Defibrillator Therapy in Patients with Ischemic or Non-Ischemic Cardiomyopathy and Nonsustained Ventricular Tachycardia
    Rudolph F. Evonich
    Alok Maheshwari
    Joseph C. Gardiner
    Atul Khasnis
    Sricharan Kantipudi
    John H. Ip
    Denise Grimes
    Gregory Hayter
    Ranjan K. Thakur
    Journal of Interventional Cardiac Electrophysiology, 2004, 11 : 59 - 65
  • [6] Primary prevention implantable cardioverter defibrillator in patients with reduced ejection fraction: for ischemic or non-ischemic cardiomyopathy or both?
    Barakat, Amr F.
    Mahmoud, Ahmed N.
    Elgendy, Islam Y.
    JOURNAL OF THORACIC DISEASE, 2017, 9 (09) : 2749 - 2751
  • [7] Incidence of mortality and appropriate shocks in patients with ischemic and non-ischemic cardiomyopathy after receiving implantable cardioverter defibrillators
    Gandhi, K.
    Aronow, W.
    Desai, H.
    Amin, H.
    Lai, H.
    Frishman, W.
    Cohen, M.
    Sorbera, C.
    EUROPEAN HEART JOURNAL, 2009, 30 : 282 - 282
  • [8] INCIDENCE OF MORTALITY AND APPROPRIATE SHOCKS IN PATIENTS WITH ISCHEMIC AND NON-ISCHEMIC CARDIOMYOPATHY AFTER RECEIVING IMPLANTABLE CARDIOVERTER DEFIBRILLATORS
    Desai, H.
    Lai, H.
    Aronow, W.
    Amin, H.
    Gandhi, K.
    Frishman, W.
    Cohen, M.
    Sorbera, C.
    JOURNAL OF INVESTIGATIVE MEDICINE, 2009, 57 (04) : 618 - 618
  • [9] Outcomes of implantable cardioverter defibrillator in patients with ischemic versus non-ischemic heart disease
    Shah, Anuj R.
    Athar, Haris
    Giedrimas, Arnoldas
    Guertin, Danette
    Giedrimiene, Dalia
    Mather, Jeff
    Clyne, Christopher
    Kluger, Jeffrey
    JOURNAL OF CARDIAC FAILURE, 2006, 12 (06) : S60 - S60
  • [10] Implantable cardioverter defibrillator in non-ischemic cardiomyopathy: a meta-analysis of randomized controlled trials
    Masri, Ahmad
    Hammadah, Muhammad
    Adelstein, Evan
    Jain, Sandeep
    Saba, Samir
    CARDIOVASCULAR DIAGNOSIS AND THERAPY, 2017, 7 (04) : 397 - +